PR
Alterity Therapeutics Limited
PRNAF · OTC
$0.06 +0.00% (+$0.00)
Market Cap $17.3M
P/E Ratio -
Div. Yield -
ROE 141.08%
Piotroski F-Score Weak
3/9Valuation
85 /100
Cheap P/B 0.41x
P/S 2.30x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 29.32%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 381.67%
Op. margin 406.17%
FCF margin 265.48%
Quality
2 /100
Poor ROE 141.08%
ROA 62.54%
Asset turnover 0.16x
Debt
94 /100
Low Current ratio 12.98x
Net debt/EBITDA 1.08x
Debt/Equity 0.00x
Stability
49 /100
Moderate EPS volatility 27.78%
Profitable years 0
Beta -0.04x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PRNAF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Stamler
Employees
11
Headquarters
Melbourne
Nadcházející události
04 BŘE
Earnings
Upcoming earnings report